SynthesisInternational journal of urology : official journal of the Japanese Urological Association2016
Active surveillance for prostate cancer.
Synthesis in International journal of urology : official journal of the Japanese Urological Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis.Journal of cancer survivorship : research and practice · 2026Pooled it
- Radical prostatectomy versus deferred treatment for localised prostate cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Prostate cancer and benign prostatic hyperplasia lesions segmentation using diffusion kurtosis imaging, T2*, and R2* mapping with U-Net++ algorithm.Radiological physics and technology · 2026Article
- Initial non-curative treatment for favorable intermediate-risk prostate cancer.International urology and nephrology · 2026Article
- Review
- Could Biparametric MRI Replace Multiparametric MRI in the Management of Prostate Cancer?Life (Basel, Switzerland) · 2023Review
- Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies.Frontiers in molecular biosciences · 2023Article
- Precision intervention for prostate cancer: Re-evaluating who is at risk.Cancer letters · 2022Review
- Article
- Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management.Biomedicines · 2021Review
- MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer.Cancers · 2021Review
- Radiomics Improves Cancer Screening and Early Detection.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Review
- Implementation of repeat biopsy and detection of cancer after a diagnosis of atypical small acinar proliferation of the prostate.Molecular and clinical oncology · 2020Article
- Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.Investigational new drugs · 2020Article
- Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.Personalized medicine · 2019Article
- The Quality of Life among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review.Healthcare (Basel, Switzerland) · 2019Review
- Interventions are needed to support patient-provider decision-making for DCIS: a scoping review.Breast cancer research and treatment · 2018Article
- Article
- A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.Clinical epigenetics · 2018Article
- Personalized medicine could transform healthcare.Biomedical reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
It is worth distinguishing between the two strategies of expectant management for prostate cancer. Watchful waiting entails administering non-curative androgen deprivation therapy to patients on development of symptomatic progression, whereas active surveillance entails delivering curative treatment on signs of disease progression. The objectives of the two management strategies and the patients enrolled in either are different: (i) to review the role of active surveillance as a management strategy for patients with low-risk prostate cancer; and (ii) review the benefits and pitfalls of active surveillance. We carried out a systematic review of active surveillance for prostate cancer in the literature using the National Center for Biotechnology Information's electronic database, PubMed. We carried out a search in English using the terms: active surveillance, prostate cancer, watchful waiting and conservative management. Selected studies were required to have a comprehensive description of the demographic and disease characteristics of the patients at the time of diagnosis, inclusion criteria for surveillance, and a protocol for the patients' follow up. Review articles were included, but not multiple papers from the same datasets. Active surveillance appears to reduce overtreatment in patients with low-risk prostate cancer without compromising cancer-specific survival at 10 years. Therefore, active surveillance is an option for select patients who want to avoid the side-effects inherent to the different types of immediate treatment. However, inclusion criteria for active surveillance and the most appropriate method of monitoring patients on active surveillance have not yet been standardized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.